Big Six firm acts in $52.5m Mesoblast placement

The firm is helping the regenerative medicine company raise capital to shore up its balance sheet

Big Six firm acts in $52.5m Mesoblast placement
MinterEllison has advised Mesoblast in completing a fully underwritten institutional placement to raise $52.5m, proceeds of which will be used to shore up the company’s balance sheet and support ongoing clinical trials and commercial manufacturing requirements.

MinterEllison’s team was led by partner Bart Oude-Vrielink, with special counsel Sudharshan
Senathirajah and Renee Doyle, and lawyer Sarah Soon.

ASIC relief to use the “cleansing notice” regime was required as Mesoblast had been suspended for more than five trading days in the past 12 months. The regenerative medicine maker’s shares were placed in a trading halt last 1 June, and then suspended two days later.

Last Monday, the firm’s shares fell more than 11%, as investors reacted to the placement of 26.25 million shares at a 16% discount to the last closing price. However, the company’s stock price has rallied nearly 60% year-to-date due to one of its drugs being awarded “fast track” designation by the US Food and Drug Administration.

Mesoblast is dual-listed on the ASX and Nasdaq.


Related stories:
New partner energises Big Six firm’s oil and gas strategy
KWM acts on $212m placement

Recent articles & video

Shelley Nave to helm Hunt & Hunt's banking and finance team

Best Law Firms in Australia and New Zealand for 2024 revealed

NSW Supreme Court to celebrate first sitting’s bicentennial with concert

ABL helps Premier Investments fashion $1bn business combo

Lisa Aitken on the gamble of starting a law firm catering to employers

Ashurst steals Kevin Harris from NRF

Most Read Articles

Herbert Smith Freehills appoints Nick Baker as managing partner

Ashurst steals Kevin Harris from NRF

Nearly a third of private practice professionals use unofficial AI for work: report

Clayton Utz to bring in Katie Higgins as partner